SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Clinical trial NCT01962441 · COMPLETED
Trial details
- NCT number
- NCT01962441
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-24
- Primary completion
- 2015-01-07
- Enrollment
- 601
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.